Pharmaceutical

Filter

Current filters:

None

Popular Filters

6676 to 6700 of 7007 results

Pfizer links up with deCODE to search for lupus drug targets

14-10-2011

Global drugs behemoth Pfizer (NYSE: PFE) has teamed up with Iceland-based genomics firm deCODE genetics,…

deCODE GeneticsLicensingPfizerPharmaceuticalRare diseasesResearch

PharmAthene files legal brief in response to SIGA's motion for reargument

14-10-2011

USA-based PharmAthene (NYSE Amex: PIP) says it has filed its legal brief in response to one-time merger…

LegalNorth AmericaPharmaceuticalPharmAtheneSIGA Technologies

Public Citizen urges US FDA to not approve ApoPharma’s iron overload drug

13-10-2011

The US Food and Drug Administration should not approve an experimental drug proposed to treat patients…

ApoPharmaApotexdeferiproneFerriproxNorth AmericaOncologyPharmaceuticalRegulation

German pharma hails progress against heart disease and rheumatism

13-10-2011

Cardiovascular disease is the most common cause of death in Germany, with 60,000 people dying of a heart…

Anti-Arthritics/RheumaticsBiotechnologyCardio-vascularEuropePharmaceuticalResearch

Flat sales at Roche as Swiss franc strength, health spending cuts and Avastin take their toll

13-10-2011

First of the drug majors to report financial results for the third quarter of 2011, Switzerland’s…

FinancialPharmaceuticalRoche

Bayer settles with Onyx over Nexavar and regorafenib with $160 million payment

13-10-2011

US drugmaker Onyx Pharmaceuticals (Nasdaq: ONXX) and German pharma major Bayer HealthCare, a unit of…

BayerLegalLicensingNexavarOncologyOnyx PharmaceuticalsPharmaceuticalregorafenib

FDA warns of pulmonary arterial hypertension risk with Bristol-Myers’ Sprycel

13-10-2011

The US Food and Drug Administration is warning the public that drug major Bristol-Myers Squibb’s…

Bristol-Myers SquibbNorth AmericaOncologyPharmaceuticalRegulationSprycel

Santen Pharma progresses acquisition of Novagali, gaining 50.55% stake

13-10-2011

Japanese drugmaker Santen Pharmaceuticals (TYO: 4536) says it has completed its previously-announced…

Mergers & AcquisitionsNovagaliOphthalmicsPharmaceuticalSanten Pharmaceuticals

Lilly’s Cialis meets endpoints in Ph III study in men with both erectile dysfunction and BPH

13-10-2011

US drug major Eli Lilly (NYSE: LLY) says that a pivotal Phase III study of its blockbuster erectile dysfunction…

CialisEli LillyPharmaceuticalReproductiveResearch

Canada would lose out on generic industry investment by adopting EU pharma proposals, warns CGPA

12-10-2011

Canada could face a loss of jobs and investment in its R&D intensive and fast-growing generic pharmaceutical…

GenericsNorth AmericaPatentsPharmaceuticalResearch

Progress on EU Information to Patients Directive welcomed by advocacy group, but still leaves problems

12-10-2011

The non-governmental organization European Public Health Alliance (EPHA) has expressed skepticism about…

EuropeMarkets & MarketingPharmaceuticalRegulation

Australian pharma industry R&D again tops A$1billion mark

12-10-2011

The Australian pharmaceutical industry’s R&D investment has exceeded A$1 billion ($984.6 million)…

Asia-PacificFinancialPharmaceuticalResearch

EMA launches database of clinical studies in children

12-10-2011

The European Medicines Agency has published a new database containing information on studies of medicines…

BiotechnologyEuropePharmaceuticalRegulationResearch

European Commission wants clearer rules for patient information on prescription medicines

12-10-2011

With the aim of empowering patients, the European Commission yesterday adopted revised proposals clarifying…

EuropeGenericsMarkets & MarketingPharmaceuticalRegulation

GlycoMimetics could earn $340 million from Pfizer in rare disease drug licensing deal

12-10-2011

Global drugs behemoth Pfizer (NYSE: PFE) has made another foray into the rare disease therapy sector,…

BiotechnologyGlycoMimeticsLicensingPfizerPharmaceuticalRare diseases

Targacept gets AstraZeneca milestone on Alzheimer’s collaboration

12-10-2011

US drug developer Targacept (Nasdaq: TRGT) says it has initiated a potential registration study of AZD3480…

AstraZenecaLicensingNeurologicalPharmaceuticalResearchTargacept

Ligand in deal with Chiva for global rights to Fablyn

12-10-2011

In a second deal with the company, Ligand Pharmaceuticals (Nasdaq: LGND) has entered into a global licensing…

Anti-Arthritics/RheumaticsChiva PharmaFablynLicensingLigand PharmaceuticalsPharmaceutical

Roche's MAb gantenerumab seen to remove amyloid plaques from the brain of Alzheimer’s patients

12-10-2011

Swiss drug major Roche (ROG: SIX) says that its monoclonal antibody gantenerumab removes amyloid plaques…

gantenerumabNeurologicalPharmaceuticalResearchRoche

Lilly promotes senior executives following two pending retirements

11-10-2011

US pharma major Eli Lilly (NYSE: LLY) has announced key appointments due to the December 31 retirements…

Eli LillyManagementPharmaceutical

Allos looks to complete merger with AMAG, as third party bows out

11-10-2011

Allos Therapeutics (Nasdaq: ALTH) says that it continues to work with fellow USA-based AMAG Pharmaceuticals…

Allos TherapeuticsAMAG PharmaceuticalsMergers & AcquisitionsPharmaceutical

Biostar to acquire Chinese firm Shaanxi Weinan for $9.6 million

11-10-2011

USA-based Biostar Pharmaceuticals (Nasdaq GM: BSPM) announced that its wholly owned subsidiary, Shaanxi…

Asia-PacificBiostar PharmaMergers & AcquisitionsPharmaceuticalShaanxi Weinan

6676 to 6700 of 7007 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top